Slide 1: Grow with Ginkgo
Filed by Soaring Eagle Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Ginkgo Bioworks, Inc. Commission File No.: 333-256121 Grow with Ginkgo Anna Marie Wagner, SVP Corporate D
Slide 2: Disclaimer
DIS CL AIMER Disclaimer This confidential presentation (the “presentation”) is being delivered to you by Soaring Eagle Acquisition Corp. (“SRNG”) and Ginkgo Bioworks, Inc. (“Ginkgo”) for use by Ginkgo and SRNG in connection with their proposed business combination and the offering of the securities
Slide 3: Disclaimer: Trademarks, Private Placement, Financial Information
DIS CL AIMER Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and SRNG’s and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks,
Slide 4: Our Mission: Make biology easier to engineer
Our Mission Make biology easier to engineer 4 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Our Mission Make biology easier to engineer 4 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021
Slide 5: We can program cells like we program computers
2006 Tom Knight with his master’s MIT,1972 thesis, a “minicomputer” We can program cells (DNA) like we program computers (code) 2019 5 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 20212006 Tom Knight with his master’s MIT,1972 thesis, a “minicomputer” We can program cells (DNA) like we p
Slide 6: Industry-defining founding team with proven executives
Combining an industry-defining founding team with proven executives who have built iconic public companies Founding team has been working together for nearly 20 years Soaring Eagle brings a track record of success in SPACs Harry Sloan Jeff Sagansky Eli Baker Reshma Shetty Jason Kelly CEO, Chairman P
Slide 7: Cell programming is increasingly impacting our lives
Cell programming is increasingly impacting our lives Ginkgo’s work to close raw material gaps in the mRNA vaccine supply chain was recently featured on 60 Minutes Vaccines are developed and manufactured using cell programming tools 7 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Cell
Slide 8: Cell programming addressing environmental and social issues
Cell programming is addressing our most challenging environmental and social issues Food & Agriculture Industrials & Environment Consumer & Technology Pharma & Biotech Nucleic acid Wastewater Renewable Animal protein Sugar Plant extracts: Haircare and Antibody vaccine remediation chemicals replaceme
Slide 9: We believe…
We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying Each new program drives We believe Ginkgo’s Each new
Slide 10: We believe… programming cells as impactful as programming computers
We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying technology can be used to create applications across
Slide 11: Program, platform and technology layers
PROGRAM LAYER Ginkgo provides program management and technical execution to product companies across all industries LEARN MORE PLATFORM LAYER Ginkgo is building the leading horizontal platform for Ginkgo is the interface cell programming across all industries between a series of complex technologies
Slide 12: We program cells for our customers
We program cells for our customers so they can develop new products 12 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We program cells for our customers so they can develop new products 12 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021
Slide 13: Major customer programs run on our platform
Over 70 major customer programs across diverse industries have run on our platform = DIVERSIFIED PLATFORM Cumulative Major 3rd Party Programs Can respond rapidly to emerging opportunities and global threats 80 + PHARMA & BIOTECH Mammalian capabilities & PRE-2015: GOVERNMENT PROGRAMS Synlogic partner
Slide 14: Customers validated the platform across end markets
Market defining customers have validated the platform across a wide range of end markets Industrials CONSUMER & TECH INDUSTRIALS & ENVIRONMENT AGRICULTURE FOOD & NUTRITION PHARMA & BIOTECH Fragrances Commodities & Specialty Chemicals Fertilizers & Crop Animal-free proteins Microbiome Therapeutics (G
Slide 15: Platform exploring diverse applications with broad partners
Ginkgo’s platform is exploring diverse applications with a broad range of partners Microbial Hosts Mammalian Hosts MAJOR PHARMA Enzyme Living Antibody Gene Discovery Therapeutics Therapeutics Therapy MULTIPLE PARTNERS Bio-process Antibiotics Optimization Discovery Animal Bio-agriculture Protein Circ
Slide 16: Platform capabilities for therapeutics discovery and manufacturing
Ginkgo’s platform has broad capabilities to accelerate and expand therapeutics discovery and manufacturing EXAMPLE CAPABILITIES EXAMPLE APPLICATIONS Enzyme Discovery & Strain Improvement Antibody & Therapeutics Optimization Our platform is well-suited to address problems HT Car Antigen Design & that
Slide 17: R&D spending accounts for nearly $40B in untapped demand
R&D spending alone accounts for nearly $40B in untapped demand Existing market for cell engineering lab operations ($B) $60 $58B Cell Engineering Labor Cell Engineering Tools $48B $50 Our scale $22 dramatically reduces costs $40B $40 $18 $33B This market represents $15 $28B $30 over 20,000+ potentia
Slide 18: $2 to $4 trillion emerging market for bioengineered products
$2 to $4 trillion emerging market for bioengineered products Annual Direct Economic Impact By Domain 2030—2040 (partial estimate) $1.2T $1.2T High Estimate Low Estimate Programming + significant secondary effects not measured biology is to the physical world what $700B programming computers is to th
Slide 19: We believe… platform improves with scale
We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program drives platform improvements, leading to more demand. 19
Slide 20: The Foundry drives a strong scale economic
The Foundry - Ginkgo’s physical infrastructure - drives a strong scale economic BW5 Lab-scale automation and significantly increased NGS capacity BW4 Added mammalian cell engineering capabilities BW3 Created scale modules by function KNIGHT’S LAW – our scale theory (e.g. DNA synthesis, -omics, BW2 s
Slide 21: Ginkgo's Foundry is scaling roughly 3x per year
Ginkgo’s Foundry is scaling roughly 3x per year L AB OPER ATIONS: MEASURING WORK DONE ON THE PLATFORM STR AIN TESTS: MEASURING THE OUTPUT OF THE PLATFORM 1,000,000 10,000,000 1,000,000 100,000 100,000 3-4x annual increase pre-COVID 10,000 10,000 1,000 1,000 2-3x annual increase pre-COVID 100 100 10
Slide 22: Unit costs to program cells decreased by 50% per year
Unit costs to program cells have decreased by 50% per year $10,000 $1,000 FOUNDRY IS 5-10X CHEAPER THAN THE STATUS QUO ESTIMATED “BY HAND” COST $100 BY 2025, WE SHOULD BE TWO ORDERS OF MAGNITUDE MORE EFFICIENT THAN “BY HAND” COVID impact $10 $1 2015 2016 2017 2018 2019 2020 2021 2025 Note: Costs inc
Slide 23: Codebase is a source of long-term competitive advantage
Codebase - Ginkgo’s scale data asset - is a source of long-term competitive advantage unique gene sequences pulled 3.4B+ from all public databases proprietary gene sequences acquired 440M And growing… codebase accumulates as we run new experiments in the foundry and build new: “Ginkgo will organize
Slide 24: We design codebase when working on programs
IMAGE CREDIT: KAREN INGRAM We design codebase when C AT T LE (BEEF & DAIRY ) INDUS T RY: working on programs (1) $1 trillion global market (2) 9% of global greenhouse gas emissions Organisms like yeast (shown above) are the biological factories for producing a wide range of molecules (1) Source: ima
Slide 25: We re-use codebase across programs
We re-use codebase across programs to improve outcomes and efficiency z C OD EB A S E The SAME YEAST used to generate proteins for food can produce proteins used in personal care products, such as collagen, elastin, and keratin 25 (1) Note targets are illustrative as Kalo has not announced specific
Slide 26: Ginkgo's virtuous cycle drives platform growth
Ginkgo’s virtuous cycle drives platform growth 26 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Ginkgo’s virtuous cycle drives platform growth 26 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021
Slide 27: We believe… Ginkgo becoming industry standard
We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We believe Ginkgo’s ecosystem of services will make us the obvious partne
Slide 28: Ecosystem will support hundreds of new cell programs a year
Our ecosystem will soon support hundreds of new cell programs a year 600 508 500 Self-Service Portals 400 Ecosystem Support 300 268 Still only 1-2% Platform Scaling of the market for 200 cell engineering (1) R&D services 136 Expand within Base 100 Leverage Proof Points 60 23 17 0 2020A 2021E 2022P 2
Slide 29: Each new program can accelerate adoption and follow-on sales
Each new cell program can accelerate adoption within new markets and lead to further sales with existing customers Ability to grow significantly within existing Early proof points within an industry customer accounts can lead to follow-on demand 12 10 (1) Major Program Minor Program Proof of Concept
Slide 30: Strong 2021 sales pipeline
Strong 2021 sales pipeline with mix of new customers and expanded relationships [CONFIDENTIAL] Kalo Launched a new spin-out in personal New relationship with Biogen to New relationship with top 5 agchem New multi-product collaboration with top global care space, with strategic and financial develop
Slide 31: Creating the industry standard ecosystem
Ginkgo is creating the industry standard ecosystem Like other horizontal tech platforms, Ginkgo is building a strong developer community - wrapping services around the platform to drive industry growth and, ultimately, demand Launched Ginkgo Ferment, our annual conference, in 2018 VIEW KEYNOTE Other
Slide 32: Expanding ecosystem of services for cell programmers
REGULATORY We will be greatly expanding our ecosystem of services for cell programmers running on the Ginkgo platform Ginkgo annual developer Open-source conference and product Source of innovative bioengineering tools showcase technologies for industry partners: hub for investment, Help drive legis
Slide 33: We believe… each program adds predictable revenue
We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program adds predictable near-term revenue from usage fees and p
Slide 34: Programs drive near-term revenues and long-term value
Programs drive both predictable near-term revenues and long-term value creation with asymmetric upside potential Foundry Downstream Value Upfront payments to cover R&D Value sharing via customer equity and/or costs for customer programs royalties on completed programs Foundry Royalty Stream Equity E
Slide 35: Program unit economics are strong and improving
Program unit economics are strong and improving FOUNDRY USAGE FEES DOWNSTREAM VALUE CAPTURE Foundry Downstream Value Ginkgo receives downstream value in multiple forms. The equity Ginkgo has steadily increased the portion of program value per program provides context for the future value. R&D costs
Slide 36: Key Financial Metrics
Key Financial Metrics (1) ($M) 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $64 $100 $175 $341 $628 $1,099 % growth 18% 57% 75% 95% 84% 75% GAAP adjustments not projected memo: GAAP Adjustments ($4) Foundry Revenue (GAAP) $59 $100 $175 $341 $628 $1,099 Emerging business, projections not pr
Slide 37: The most powerful technologies require the most care
The most powerful technologies require the most care Our culture is built on care, transparency, diversity, employee ownership and a deep, humble respect for biology. We take care in considering which programs we pursue We invest in our and which we do not, and explore the implications of biotechnol
Slide 38: We believe… We hope…
We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We hope… …that when technology meets biology, life finds a way. Anna Mari
Slide 39: Additional Legal Information: Forward-Looking Statements
ADDITIONAL LEGAL INFORMATION Forward-Looking Statements Legend This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo Bioworks, Inc. (“Ginkgo Bioworks”) and Soaring Eagle Acquisition Corp. (“